For the year ending 2025-12-31, MXCT had -$7,819K decrease in cash & cash equivalents over the period. -$36,178K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -44,630 |
| Depreciation and amortization | 4,340 |
| Goodwill impairment | 3,554 |
| Lease right-of-use asset amortization | 802 |
| Net book value of consigned equipment sold | 83 |
| Loss on disposal of property and equipment | -287 |
| Stock-based compensation | 9,213 |
| Credit loss expense (recovery) | 35 |
| Change in excess/obsolete inventory reserve | 676 |
| Amortization of discounts on investments | 2,646 |
| Accounts receivable | -1,148 |
| Inventory | -575 |
| Prepaid expense and other current assets | 531 |
| Other assets | 724 |
| Accounts payable, accrued expenses and other | -3,721 |
| Operating lease liability | -1,157 |
| Deferred revenue | -1,678 |
| Other liabilities | -36 |
| Net cash used in operating activities | -34,410 |
| Purchases of investments | 126,286 |
| Maturities of investments | 155,762 |
| Purchases of property and equipment | 1,768 |
| Acquisition of business, net of cash acquired of 541 | 1,773 |
| Net cash provided by investing activities | 25,935 |
| Proceeds from exercise of stock options | 432 |
| Proceeds from issuance of common stock under employee stock purchase plan | 224 |
| Net cash provided by financing activities | 656 |
| Net decrease in cash and cash equivalents | -7,819 |
| Cash and cash equivalents, beginning of year | 27,884 |
| Cash and cash equivalents, end of year | 20,065 |
MAXCYTE, INC. (MXCT)
MAXCYTE, INC. (MXCT)